Amgen Inc. (NASDAQ:AMGN) had its price target upped by equities researchers at Barclays PLC from $180.00 to $190.00 in a research report issued on Friday. The brokerage presently has an “equal weight” rating on the medical research company’s stock. Barclays PLC’s target price would suggest a potential upside of 3.96% from the company’s current price.
Several other research firms also recently commented on AMGN. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $203.00 price objective (up from $189.00) on shares of Amgen in a report on Wednesday, July 26th. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, June 23rd. ValuEngine upgraded Amgen from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. BMO Capital Markets downgraded Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, July 26th. Finally, Mizuho reiterated a “buy” rating and issued a $198.00 price objective (up from $183.00) on shares of Amgen in a report on Thursday, September 28th. Eleven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $189.99.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. During the same period last year, the company earned $2.84 EPS. Amgen’s revenue for the quarter was up 2.1% on a year-over-year basis.
TRADEMARK VIOLATION NOTICE: “Barclays PLC Raises Amgen Inc. (AMGN) Price Target to $190.00” was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.truebluetribune.com/2017/10/13/barclays-plc-raises-amgen-inc-amgn-price-target-to-190-00.html.
In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.19% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. TrimTabs Asset Management LLC lifted its holdings in Amgen by 88.9% in the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after purchasing an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC lifted its holdings in Amgen by 19.0% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after purchasing an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. lifted its holdings in Amgen by 0.6% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after purchasing an additional 4 shares in the last quarter. Phocas Financial Corp. purchased a new position in Amgen in the 2nd quarter worth approximately $110,000. Finally, American Beacon Advisors Inc. purchased a new position in Amgen in the 1st quarter worth approximately $106,000. 78.10% of the stock is currently owned by institutional investors.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.